Recombinant E.coli GCY1 protein

GCY1 recombinant protein is derived from the GCY1 gene, which encodes a member of the guanylate cyclase family involved in cyclic GMP (cGMP) signaling. Guanylate cyclases catalyze the conversion of GTP to cGMP, a critical secondary messenger regulating diverse physiological processes, including vascular homeostasis, neurotransmission, and cell proliferation. The GCY1 isoform, particularly studied in model organisms like *Saccharomyces cerevisiae*, functions as a NADPH-dependent glyceraldehyde dehydrogenase in certain metabolic pathways, though its precise role varies across species. In humans, homologs of guanylate cyclases are linked to sensory and cardiovascular functions, with mutations associated with diseases such as retinal degeneration and hypertension.

Recombinant GCY1 protein is produced using biotechnological methods, often expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. This engineered protein retains enzymatic activity, enabling researchers to study its biochemical properties, substrate specificity, and interaction partners *in vitro*. Its applications span basic research—elucidating cGMP-dependent signaling mechanisms—and drug discovery, where it serves as a target for modulating cGMP levels in pathologies like heart failure or pulmonary disorders. Additionally, GCY1 recombinant protein is utilized in diagnostic assays to detect cGMP-related pathway abnormalities. By providing a purified, functional form of the enzyme, it accelerates structural studies (e.g., crystallography) and the development of therapeutics targeting guanylate cyclase pathways. Overall, GCY1 recombinant protein is a vital tool for unraveling the complexity of cGMP signaling and its implications in health and disease.